Nitric oxide maintains endothelial redox homeostasis through PKM2 inhibition

EMBO J. 2019 Sep 2;38(17):e100938. doi: 10.15252/embj.2018100938. Epub 2019 Jul 22.

Abstract

Decreased nitric oxide (NO) bioavailability and oxidative stress are hallmarks of endothelial dysfunction and cardiovascular diseases. Although numerous proteins are S-nitrosated, whether and how changes in protein S-nitrosation influence endothelial function under pathophysiological conditions remains unknown. We report that active endothelial NO synthase (eNOS) interacts with and S-nitrosates pyruvate kinase M2 (PKM2), which reduces PKM2 activity. PKM2 inhibition increases substrate flux through the pentose phosphate pathway to generate reducing equivalents (NADPH and GSH) and protect against oxidative stress. In mice, the Tyr656 to Phe mutation renders eNOS insensitive to inactivation by oxidative stress and prevents the decrease in PKM2 S-nitrosation and reducing equivalents, thereby delaying cardiovascular disease development. These findings highlight a novel mechanism linking NO bioavailability to antioxidant responses in endothelial cells through S-nitrosation and inhibition of PKM2.

Keywords: Pyruvate kinase M2; S-nitrosation; cardiovascular disease; eNOS tyrosine phosphorylation; endothelial dysfunction.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Substitution*
  • Animals
  • Cells, Cultured
  • Endothelial Cells
  • Homeostasis
  • Humans
  • Male
  • Mice
  • Nitric Oxide / metabolism*
  • Nitric Oxide Synthase Type III / genetics
  • Nitric Oxide Synthase Type III / metabolism*
  • Oxidation-Reduction
  • Pentose Phosphate Pathway
  • Protein Binding
  • Pyruvate Kinase / metabolism*

Substances

  • Nitric Oxide
  • Nitric Oxide Synthase Type III
  • Nos3 protein, mouse
  • Pkm protein, mouse
  • Pyruvate Kinase